Western University, Canada - London Ontario
|
Tuesday May 21, 2013
7:39 PM
EBN Navigation
Cognitive /
Behavioural (10)
Critical Care (7)
Demyelinating Disease
(9)
Epilepsy
(18)
August 1998
There seems to be no significant difference among the new AED's effectiveness as add-on therapy for refractory partial seizures.ID
#9 | August 1998 | PDF DocumentSpecialty : Epilepsy | Category : Therapy- In patients who have been seizure free for 2 years, slow withdrawal of anti-epileptic medication increases their risk of seizure recurrence by
at least 19% at 2 years.ID #5 | August 1998 | PDF DocumentSpecialty
: Epilepsy | Category : Prognosis
- In healthy adults with a first generalized seizure and normal
neurologic exam, the diagnostic yield (etiologically relevant) of outpatient investigations is: CT head=5%, EEG=60%, LABS=5%. With focal neurologic deficit the yield of brain imaging =
75%.ID #6 | August 1998 | PDF DocumentSpecialty : Epilepsy
| Categories : Diagnosis, Prognosis
Headache (9)
April 2003
- All triptans were effective and well tolerated in
treatment of acute migraine. Compared with 100 mg sumatriptan, 12.5 mg rizatriptan and 80 mg eletriptan were slightly more efficacious; 12.5 mg almotriptan was similarly efficacious but better
tolerated.ID #88 | April 2003 | PDF DocumentSpecialty :
Headache | Category : Therapy
- Carbamazepine was effective in the short-term management of trigeminal neuralgia (NNT 2.6 vs.
placebo). No drugs have demonstrated superiority in monotherapy. Surgery has not been adequately evaluated.ID #89 | April 2003 | PDF
DocumentSpecialty : Headache | Category :
Therapy
Infection (8)
Movement Disorders (12)
November 2009
- Early monotherapy with rasagiline for symptomatic management of Parkinson's Disease was efficacious, but there was insufficient evidence of
neuroprotection.ID #153 | November 2009 | PDF DocumentSpecialty :
Movement Disorders | Category : Therapy
- Early monotherapy with rasagiline was efficacious for symptomatic management of Parkinson's Disease, but there wasinsufficient evidence
ofneuroprotection.ID #169 | November 2009 | PDF DocumentSpecialty :
Movement Disorders | Category : Therapy
May 2005
- In the treatment of neurogenic orthostatic hypotension, midodrine
increased standing systolic blood pressure and resulted in a small improvement in symptomatic scores. The clinical significance of this is uncertain.ID #121
| May 2005 | PDF DocumentSpecialties : Movement Disorders, Other | Category : Therapy
- There was an
association between coffee consumption and the risk of developing Parkinson's disease.ID #120 | May 2005 | PDF DocumentSpecialty : Movement Disorders | Category :
Diagnosis
Neurological Exam (3)
Neuromuscular (34)
October 1999
- Weak evidence suggested that surgical decompression was effective for all levels of severity of ulnar nerve compression at the elbow (77-89%
chance of improvement).ID #30 | October 1999 | PDF DocumentSpecialty
: Neuromuscular | Category : Therapy
- With conservative management alone, 42% of mild cases of
ulnar neuropathies and 20% of severe cases became symptom free;79% improved and 21% worsened. Surgery was required in 21% of mild cases and 62% of severe cases, typically within 2 years.ID #29 | October 1999 | PDF DocumentSpecialty : Neuromuscular
| Categories : Prognosis, Therapy
April 1999
- Intramuscular injections
of gangliosides do not alter progressive deterioration of ALS.ID #19 | April 1999 | PDF DocumentSpecialty : Neuromuscular | Categories : Prognosis, Therapy
- Overall, immune suppressants and modulating agents do not alter disease progression in ALS. Weak support for benefit with cyclosporine in early
stages of ALS.ID #20 | April 1999 | PDF DocumentSpecialty :
Neuromuscular | Categories : Prognosis, Therapy
- rhIGF-I may slow progression of functional impairment and the decline in health-related quality of life in ALS patients while
rhCNTF and TRH do not alter clinical progression of ALS.ID #24 | April 1999 | PDF DocumentSpecialty : Neuromuscular | Categories : Prognosis, Therapy
- Riluzole appears to minimally improve survival in ALS. All other therapeutic trials of anti-glutamatergic and anti-excitotoxicity
agents reveal no significant effect.ID #23 | April 1999 | PDF DocumentSpecialty : Neuromuscular | Category : Therapy
- The
NMJ "enhancers" physostigmine, neostigmine, and 3,4-DAP do not improve motor function in ALS.ID #17 | April 1999 | PDF
DocumentSpecialty : Neuromuscular | Category :
Therapy
- Treatment of ALS with Modified Snake Venom did not alter clinical progression. Tilorone could actually cause harm.ID #22 | April
1999 | PDF DocumentSpecialty : Neuromuscular | Categories :
Harm, Prognosis, Therapy
- Treatment of ALS
with selegiline or L-Dopa does not alter the rate of clinical deterioration.ID #21 | April 1999 | PDF DocumentSpecialty : Neuromuscular | Category : Therapy
January 1999
Neurosurgery (9)
Oncology
(9)
Other (18)
January 2004
- Bed rest was no
better than immediate mobilization to prevent post-lumbar puncture headache.ID #100 | January 2004 | PDF DocumentSpecialty : Other | Category : Therapy
- Canalith
repositioning maneuvres shortened the duration of benign paroxysmal positional vertigo.ID #98 | January 2004 | PDF DocumentSpecialty : Other | Category : Therapy
February 2002
- Clopidogrel plus aspirin therapy for acute coronary
syndromes without ST-elevation modestly reduced the risk of myocardial infarction (NNT 40) and the composite outcome of cardiovascular death, non-fatal MI, stroke OR refractory ischemia (NNT
43).ID #68 | February 2002 | PDF DocumentSpecialties : Other,
Vascular/Stroke | Categories : Prognosis, Therapy
- Depressed elderly outpatients and inpatients improved in depression scores by treating with TCA's (NNT 4), and SSRI's (NNT 8).ID #69
| February 2002 | PDF DocumentSpecialty : Other | Category
: Therapy
Pain
(3)
Sleep Disorders (2)
Vascular/Stroke (49)
October 2001
- In patients with a first attack of unifocal or multifocal MS and a positive MRI, early Interferon delayed the development of a second attack
(Clinically Definite MS).ID #63 | October 2001 | PDF DocumentSpecialty
: Vascular/Stroke | Category : Therapy
- In patients with GBS, the following factors predicted poor outcome: inability to walk independently at 8 weeks, age >
50 years, preceding gastrointestinal illness, and MRC sum score <40.ID #62 | October 2001 | PDF DocumentSpecialty : Vascular/Stroke | Category :
Prognosis
-
Michael J. Strong
MD, FRCP(C), FANN, FCAHS
- Neurodegeration / Regeneration
- Neuromuscular Disease
- View Dr. Strong's Bio...
-
Matthew Hebb
MD, PhD, FRCSC
- Academic Specialized Treatment
- Neurodegeration / Regeneration
- View Dr. Hebb's Bio...
